Abpro Bio Co., Ltd. Overview
RootK is a Daegu-based maker of small machining centres and tapping machines, a niche in the metal-cutting machine tool industry. It has gone through two corporate reinventions in seven years. Listed in 2015 as Ugint, it was taken over in 2019 by investors associated with former KH Feelux CEO Ahn Won-hwan. It was renamed Abpro Bio and repositioned as a bispecific-antibody drug developer through a controlling investment in US-based Abpro Corporation (later Abpro Holdings, Inc.). That biotech strategy consumed more than KRW 100 bn of invested capital. It ended in 2026 with Abpro Holdings delisted from Nasdaq, its R&D staff dismissed, and roughly KRW 150 bn of impairments recognised over about a year. After a 90% capital reduction, a KRW 4 bn rights issue and a change of control to Returns, the company adopted the RootK name. It also added entertainment, content, logistics and advertising business purposes. Today it is a loss-making, capital-impaired micro-cap with an unproven new strategy.
What the company does today. RootK's only revenue-generating operation that can be verified is its legacy machine tool business. This covers the design, manufacture and sale of compact vertical machining centres (MCT) and tapping machines, plus original equipment manufacturing (OEM) work. Saramin lists the business as tapping machine manufacturing and the industry as metal-cutting machine manufacturing (금속 절삭기계 제조업). IRGO lists the main product as small machining centres. Alpha Spread notes the OEM business. Korean Wikipedia (2026) still describes RootK as a manufacturer of machining centres.
Company's own description. The full business description in the latest annual report (FY2025, filed March 2026) could not be retrieved. The June 2026 EGM agenda, as reported by Green Economy (8 Jun 2026) and Press9 (May 2026), shows how management now describes the company's scope. Unused objects such as nuclear decommissioning were deleted. Entertainment-related objects were added: wholesale and retail of records and video, performance planning, event agency, and popular culture and arts planning. Press9 counted 12 new business purposes in total, spanning music, video, logistics and advertising.
Independent characterisation. RootK is best understood as three layers:
-
An operating core (machine tools). This is a small, cyclical capital-goods business. Its revenue fell sharply in FY2025: separate-entity sales reportedly went from KRW 18.4 bn in FY2024 to KRW 5.1 bn in FY2025 (Green Economy, Apr & Jun 2026). Catch shows KRW 5.2 bn separate revenue for FY2025.
-
A residual biotech stake. This is an equity-method interest in Abpro Holdings, Inc. Green Economy (Apr 2026) cites a 32.47% holding. Abpro Holdings is now traded on OTC Pink (ABPO) after Nasdaq delisting, with near-zero R&D activity. Its book value was only KRW 4.8 bn at Q3 2025 against KRW 104.3 bn invested (Green Economy, Mar 2026).
-
An announced pivot to entertainment and content. It has no disclosed revenue, contracts or acquisitions yet. It is driven by the new controlling shareholder, Returns, whose sole registered director, Lee Sung-jae, is also sole director of Nestree Media Group, in which Cube Entertainment holds 40% (Green Economy, Jun 2026).
Business model and revenue mix.
Unexplained consolidated revenue. Consolidated revenue was KRW 31.7 bn in FY2024 and KRW 31.9 bn in FY2025 (ChickStock; Meerae AI). Separate-entity machine tool revenue was KRW 18.4 bn and KRW 5.1–5.2 bn. That implies other consolidated revenue of roughly KRW 13.3 bn in FY2024 and KRW 26.8 bn in FY2025 (derived). Its source — which subsidiary and which product — is not publicly disclosed in the sources accessed.
Value chain position. In machine tools, RootK is a mid-stream equipment assembler. It buys castings, spindles, CNC controllers and linear guides and sells finished machines to metalworking job shops and component makers, some of it on an OEM basis. Customer types and end-markets: customer names are not publicly disclosed. Compact machining and tapping centres are typically used for high-volume drilling and tapping of small parts in IT devices, automotive components and general machinery. This is an industry characterisation, not a company disclosure.
Strategy
Stated strategy themes. No annual report strategy section or investor day material could be verified. Strategy is inferred from formal corporate actions.
-
Exit from biotech identity. The company dropped "Bio" from its name, renamed itself RootK and deleted unused business purposes (Press9; Green Economy, Jun 2026). Green Economy characterises this as a full identity pivot after more than KRW 100 bn was spent on biotech without results.
-
Entertainment and content entry. New business purposes cover records and video distribution, performance planning, event agency and entertainment management (Green Economy, Jun 2026). Logistics and advertising purposes were also added (Press9). The new owner's links to Nestree Media Group (40% Cube Entertainment) and the Nestree cryptocurrency point to the likely direction. Green Economy flagged a possible move into digital assets; this is not confirmed by any company filing.
-
Balance-sheet repair to protect the listing. Initiatives over the last 24 months include the 90% capital reduction (Jan–Feb 2026), the KRW 4 bn third-party rights issue, KRW 6 bn of CBs (18th and 19th, March 2026; Edaily puts the dilution at about 15% of shares outstanding), and a share consolidation (July 2026). The consolidation is consistent with KOSDAQ's 2026 tightening of minimum price rules. Fnnews (Aug 2026) notes that companies designated for low price must hold KRW 1,000 or more for 45 consecutive trading days within 90 trading days after relisting.
-
Ongoing outbound investment. The 18th CB proceeds are earmarked for "acquisition of other companies' securities" (Green Economy, Mar 2026). No target has been publicly identified.
ESG or sustainability commitments, cost programmes with targets, medium-term financial targets and guidance: none publicly disclosed.
Products & Services
Machine tools (operating business)
| Product line | Description | Key specs / capabilities | Target customer | Launch / latest version | Pricing | Source |
|---|---|---|---|---|---|---|
| Small (compact) vertical machining centres (MCT) | CNC machines for milling, drilling and tapping small workpieces | Model-level specifications not publicly disclosed in sources accessed | Metalworking shops; small-part manufacturers | — | — | IRGO; Wikipedia |
| Tapping machines / tapping centres | High-speed drilling and tapping machines | — | High-volume part producers | — | — | Saramin ("탭핑머신 제조") |
| OEM manufacturing | Manufacturing machines for other brands | — | Machine tool brands / distributors | — | — | Alpha Spread |
| COVID-19 mask production equipment (historic, 2020) | Mask-making machines built on in-house equipment know-how | — | Mask producers | 2,020 | ND; described as high-margin at the time | Dealsite, Jul 2020 |
Biotech pipeline (held via Abpro Holdings — affiliate, not consolidated operations)
| Candidate | Modality / target | Indication | Partner | Stage (latest public) | Source |
|---|---|---|---|---|---|
| ABP-102 / CT-P72 | Tetravalent bispecific (TetraBi) HER2×CD3 T-cell engager | HER2-positive solid tumours (breast, gastric, pancreatic) | Celltrion (global rights since Sep 2022; funds all development) | IND submitted 15 Dec 2025; FDA IND clearance announced shortly after; preclinical data at AACR 2025 and SITC 2025 (oral) | Abpro releases (zonebourse list); Asia Economy, Nov 2025; roic.ai |
| ABP-201 | TetraBi VEGF × ANG-2 | Diabetic macular oedema; wet AMD | None disclosed | Preclinical; Phase 1 targeted for H1 2021 per 2020 CEO interview (no evidence it began) | Yahoo Finance profile; Dealsite, Jul 2020; Asia Economy, Oct 2019 |
| ABP-110 | TetraBi GPC3 × CD3 | Hepatocellular carcinoma | — | Preclinical | Yahoo Finance profile |
| ABP-150 | TetraBi Claudin 18.2 × CD3 | Gastric cancer | — | Preclinical | Yahoo Finance profile |
| ABP-100 | Immuno-oncology bispecific | Solid tumours | — | US Phase 1 targeted for H2 2020 (no evidence it began) | Dealsite, Jul 2020; fool.com |
| ABP-130 | Immuno-oncology | Haematological cancer | — | Discovery (2019 mention) | Asia Economy, Oct 2019 |
| COVID-19 antibody | Antibody | COVID-19 | — | Pre-commercial | fool.com |
Entertainment / content (announced, Jun 2026)
| Business purpose added | Products / services disclosed | Revenue | Source |
|---|---|---|---|
| Record & video wholesale/retail | None disclosed | — | Green Economy, Jun 2026 |
| Performance planning | None disclosed | — | Green Economy, Jun 2026 |
| Event agency | None disclosed | — | Green Economy, Jun 2026 |
| Popular culture & arts planning (entertainment management) | None disclosed | — | Green Economy, Jun 2026 |
| Logistics, advertising and other objects (12 new purposes in total) | None disclosed | — | Press9, May 2026 |
Financial Narrative
Data availability. Consolidated figures could be verified for FY2022–FY2025 (ChickStock, from DART). Gross profit, EBITDA, pre-tax income, EPS history and full cash-flow statements are not publicly disclosed in the sources accessed. Ratios marked "derived" are analyst calculations from reported figures.
Income statement: notes and sources
Source: ChickStock financials page (DART filings, FY2022–FY2025). FY2025 is corroborated by Meerae AI and Korean Wikipedia: revenue KRW 31,922,791,800; operating loss KRW 9,281,936,003; net loss KRW 48,919,928,977.
Margins and growth (derived)
ChickStock reports FY2025 growth as +0.8%, a rounding difference. Revenue CAGR FY2022–FY2025: about 13.0% per year (derived: (31.9/22.1)^(1/3) − 1).
Earlier history
Operating income on the same basis: FY2019 −21.3; FY2020 1.5 (sign implied positive); FY2021 −4.5; FY2022 −5.9 (IB Tomato, 2023). The FY2022 values (net −6.8, operating −5.9) differ from the consolidated figures (−8.1, −8.6), which suggests these are separate-entity numbers. Cumulative net losses FY2017–FY2025 exceed KRW 160 bn, combining the separate series to FY2021 with the consolidated series from FY2022 (derived, mixed basis).
Balance sheet
Sources: Green Economy (Mar 2026) gives FY2024 equity of KRW 108.1 bn and FY2025 equity of KRW 54.2 bn (pre-audit). Meerae AI gives audited FY2025 equity of KRW 54.0 bn. Capital impairment ratios are from Green Economy and Edaily (Mar 2026).
FY2025 consolidated balance sheet snapshot (Meerae AI; ChickStock):
Q1 2025 snapshot (Simply Wall St / S&P Global): total assets 138.5; total liabilities 33.7; equity 104.9; total debt 21.2; cash 18.25; debt/equity 20.2%. Implied net debt was about KRW 3.0 bn (derived). Total assets almost halved between Q1 2025 and end-2025, mostly because of the impairments.
Cash and equivalents, short/long debt split, goodwill and intangibles, and working capital at FY2025 are not publicly disclosed in the sources accessed. Separate-entity current ratios: FY2020 412.95%; FY2021 275.21%; FY2022 286.04%; Q1 2023 215.08% (IB Tomato).
Commentary on trends and drivers
Operating losses are structural. RootK has posted consolidated operating losses of KRW 8.6–10.2 bn in each of the last four years. ChickStock flags three consecutive years of operating losses as a "marginal company" signal. Loss levels have stayed flat even as consolidated revenue rose, so the cost base — including listed-company overheads and affiliate-related costs — is not scaling with sales.
Net losses are driven by investments, not operations. The gap between operating loss (−9.3 bn) and net loss (−48.9 bn) in FY2025 reflects write-downs on the Abpro investment chain. Green Economy (Mar 2026) estimates about KRW 150 bn of investment impairments over roughly a year. These include the KRW 42.5 bn Abpro Bio International write-off, loan and receivable impairments of 6.7 bn and 7.9 bn, and an apparent write-off of about KRW 50.1 bn of loans to that subsidiary. They also include more than KRW 100 bn of impairment on KRW 104.3 bn invested in Abpro Holdings.
The equity base has been halved. Equity fell from KRW 108.1 bn to KRW 54.0 bn in one year, and the capital impairment ratio rose to 61.8%. Under KOSDAQ rules, impairment of 50% or more at year-end triggers administrative-issue designation, and repetition leads to delisting review (IB Tomato, 2023; Edaily, Mar 2026). The 90% capital reduction (record date 23 Feb 2026) was a technical fix: it cuts share capital so that the same equity no longer counts as "impaired". It did not add any economic value.
Revenue quality has deteriorated. The legacy machine tool business shrank by roughly 72% in FY2025, while a residual of about KRW 26.8 bn from undisclosed sources kept consolidated revenue flat. Q1 2026 consolidated revenue was KRW 7.9 bn, down 11.1% YoY (ChickStock).
Funding dependence. Negative operating cash flow (−6.7 bn in FY2025) is being funded through dilutive equity and convertible bonds. In March 2026 the company raised a KRW 4 bn rights issue and two KRW 3 bn CBs. Green Economy reports that the 18th CB, subscribed by 라은컴퍼니 (formerly 원진홀딩스, a company founded by Ahn Won-hwan), was earmarked for acquiring other companies' securities. Critics see this as continuing the past pattern of outbound investment followed by impairment.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Function | Status | Source |
|---|---|---|---|---|
RootK Co., Ltd. (formerly Abpro Bio) | Listed parent | Machine tools (MCT, tapping), OEM; new entertainment purposes | Active; KOSDAQ administrative issue | Saramin; Catch |
Abpro Bio International, Inc. (US) | Subsidiary, est. Nov 2019 | Holding vehicle for Abpro investment | Fully impaired FY2024 (KRW 42.5 bn); fully capital-impaired at end-2024 | Green Economy, Mar 2026 |
Abpro Holdings, Inc. (US; formerly Abpro Corporation) | Affiliate (32.47% cited) | Bispecific antibody R&D (ABP-102, ABP-201, others) | Nasdaq delisted Jun 2026; OTC Pink ABPO; R&D staff dismissed | Green Economy; SEC 10-Q Q2 2026 |
Abpro Pharma (에이비프로파마) | Subsidiary | — | Loans and investment fully impaired FY2024 | Green Economy, Mar 2026 |
Ludens Development (루덴스개발) | Former subsidiary | Philippine casino stake/licences | Sold 2021 | Green Economy, Mar 2026 |
ACT (액트) | Former subsidiary | — | Sold 2021 for KRW 3 m | Green Economy, Mar 2026 |
TS Co. (티에스) | Former subsidiary | Not disclosed (2020) | Established Jan 2020, sold Jun 2020 | Saramin |
“—” = not publicly disclosed.
Segment / revenue line (KRW Bn)
| Segment / revenue line (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Machine tools — separate entity revenue (KRW Bn) | 18.4 | 5.1 |
Consolidated revenue — total (KRW Bn) | 31.7 | 31.9 |
Other consolidated revenue — derived residual (KRW Bn) | 13.3 | 26.8 |
Segment share of consolidated revenue (%)
| Segment share of consolidated revenue (%) | FY2024 | FY2025 |
|---|---|---|
Machine tools — separate entity (%) | 58.0 | 16.0 |
Other consolidated — residual (%) | 42.0 | 84.0 |
Income Statement
| Metric (consolidated, KRW Bn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue (KRW Bn) | 22.1 | 25.4 | 31.7 | 31.9 |
Operating income (KRW Bn) | -8.6 | -8.8 | -10.2 | -9.3 |
Net income (KRW Bn) | -8.1 | -25.7 | -15.6 | -48.9 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Operating margin (%) | -38.9 | -34.6 | -32.2 | -29.2 |
Net margin (%) | -36.7 | -101.2 | -49.2 | -153.3 |
Revenue growth YoY (%) | 0 | 14.9 | 24.8 | 0.6 |
Income Statement (FY2017–FY2022)
| Metric (KRW Bn, as reported by IB Tomato) | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
Net income (KRW Bn) | -13.5 | -11.5 | -33.8 | -52.7 | -4.4 | -6.8 |
Balance Sheet and Margin Analysis (%)
| Metric (consolidated, KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Total equity (KRW Bn) | 108.1 | 54.0 |
Capital impairment ratio (%) | 24.1 | 61.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Item | FY2025 (KRW Bn) |
|---|---|
Total assets | 74.8 |
Total liabilities | 20.7 |
Total equity | 54.0 |
Share capital (자본금) | 142.3 (before the 90% capital reduction effective Feb 2026) |
Liabilities / equity | 38.4% |
Operating cash flow | −6.7 |
Financial Analysis — Operating cash flow
| Item | FY2025 (KRW Bn) | Source |
|---|---|---|
Operating cash flow | −6.7 | ChickStock (FY2025 annual report) |
Free cash flow | ND (OCF alone negative) | — |
Dividends paid | 0 (no dividend record) | Simply Wall St |
Buybacks | 0 (none disclosed) | Simply Wall St |
Financial Analysis — ROE
| Ratio | Value | Period | Basis |
|---|---|---|---|
ROE | −90.5% | FY2025 | Meerae AI |
ROE | −17.3% | TTM to Q1 2025 | Simply Wall St |
ROE | −19.2% | 2026 (TTM, aggregator) | ChickStock |
ROA | −65.4% | FY2025 | Derived (net loss / year-end assets) |
Current ratio | ND (FY2025) | — | — |
Debt / equity | 20.2% | Q1 2025 | Simply Wall St |
Liabilities / equity | 38.4% | FY2025 | Meerae AI |
Net debt / EBITDA | Not meaningful (EBITDA negative) | — | — |
Interest coverage | Not meaningful (operating loss) | — | — |
Asset turnover | 0.43x | FY2025 | Derived (31.9 / 74.8) |
BPS | KRW 3,317 / KRW 3,219 | 2026 | ChickStock / KStock (post capital reduction) |
EPS (TTM) | −KRW 1,502 / −KRW 343 | 2026 | KStock / Judal (differing bases) |
Region revenue (KRW Bn)
| Region revenue (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Total consolidated (all regions; split not disclosed) (KRW Bn) | 31.7 | 31.9 |
Share Price History
| Date | Price (KRW) | Context | Source |
|---|---|---|---|
5 Nov 2025 | 243 | +29.95% intraday on SITC news (pre-capital reduction) | Asia Economy |
6 Jan 2026 | 209 | −22.88% on 10:1 capital reduction announcement | Seoul Economic Daily |
3 Jul 2026 | ≈ 700 (open 708, high 727, low 672) | Market cap KRW 22.9 bn | Meerae AI |
14–23 Jul 2026 | 630 (no volume) | Suspended for share consolidation | Asia Economy quote box; KStock |
11 Aug 2026 | 1,360 | After consolidation (+3.82% on day) | Asia Economy quote box |
10–12 Oct 2026 | 1,103 | Market cap KRW 17.9 bn; P/B 0.35x | Judal; Asia Economy quote box |
Valuation Multiples
| Multiple | RootK | Source / basis |
|---|---|---|
P/E | Not meaningful (losses) | Judal |
P/B | 0.35x (Oct 2026); 0.2x (Jul 2026) | Judal; KStock |
P/Sales | ≈ 0.56x (derived: 17.9 / 31.9); 3.0x (Mar 2025) and 4.2x (Dec 2024), when the Korean machinery median was below 0.9x | Derived; Simply Wall St |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
Capital Markets
| Item | Status | Source |
|---|---|---|
Analyst coverage | None (last broker reports June 2015) | Simply Wall St; IRGO |
Dividend history / policy | No dividend record | Simply Wall St |
Buyback authorisations | None disclosed | Simply Wall St |
Credit ratings (Moody's / S&P / Fitch) | None. A Catch listing shows a commercial credit grade "양호" (Apr 2026); this is not an agency rating | Catch |
Debt maturity profile | 18th/19th CBs issued Mar 2026 (KRW 3 bn each); maturities and terms ND | Green Economy |
Listing | OTC Pink: ABPO (common), ABPWW (warrants) | SEC 10-Q, Q2 2026 |
Last close | USD 0.21 (17 Aug 2026) | fool.com |
YTD 2026 return | −95.08% | fool.com |
Return since 2022 SPAC IPO | −99.93% | fool.com |
Analyst Conclusions
Management guidance. None published. Consensus. No coverage, so no consensus estimates exist (Simply Wall St).
Bull case (grounded in data)
-
Asset value floor. At P/B of about 0.35x (Judal, Oct 2026) and equity of about KRW 54 bn at FY2025 against a market cap of about KRW 18 bn, the market discounts the balance sheet heavily. If remaining assets (plant, receivables, residual stakes) hold value and losses narrow, the discount could close.
-
ABP-102 optionality at near-zero carrying cost. The IND is cleared and Celltrion bears development costs. The Abpro stake is booked at only KRW 4.8 bn (Q3 2025). A Phase 1 start by Celltrion could re-rate Abpro from its USD 0.21 OTC level.
-
New owner's entertainment network. Links to Nestree Media Group and Cube Entertainment could bring in a revenue-generating content business. The listed shell, with its existing manufacturing revenue, gives a ready vehicle.
Bear case (grounded in data)
-
Delisting arithmetic. Capital impairment of 61.8% at FY2025, administrative-issue status, and a market cap of about KRW 17.9 bn versus the KRW 20 bn KOSDAQ standard leave little margin. Any further impairment or a failure to sustain prices above KRW 1,000 could trigger delisting review.
-
The core business is shrinking and losses are sticky. Separate machine tool revenue fell about 72% in FY2025. Operating losses have held at KRW 8.6–10.2 bn for four years, and OCF was −KRW 6.7 bn. The company depends on dilutive financing to survive.
-
The capital-allocation track record is poor and continuing. Assets were bought and then sold at 88% to almost 100% losses (Ludens, ACT), more than KRW 100 bn was impaired on Abpro, and CB proceeds are again earmarked for unnamed outside investments. Combined with an asset-light new owner funded by borrowings, minority shareholders face high expropriation and dilution risk.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters |
|---|---|
| H1 2026 and Q3 2026 reports (Aug / Nov 2026) | Machine tool revenue trend; source of the residual consolidated revenue; further impairments; cash position |
| FY2026 year-end capital impairment ratio (Mar 2027 annual report) | A second year at 50% or more would escalate delisting risk |
| Share price vs KRW 1,000 and market cap vs KRW 20 bn | KOSDAQ administrative-issue thresholds |
| Use of 18th CB proceeds; any acquisition announcement | Risk of repeating past value destruction, or a real entertainment asset injection |
| CB conversions and any new equity issues | Dilution |
| Celltrion's decision on ABP-102 Phase 1 initiation | Residual value of the Abpro stake |
| Abpro Holdings' going-concern resolution or wind-down | Possible final write-off |
| Further board or ownership changes | Governance stability |
Concluding analyst verdict
RootK is not an operating story but a governance and solvency story. The verifiable facts point clearly in one direction. Over seven years the company used its listing to raise capital for successive pivots: casino-linked subsidiaries, COVID equipment, a semiconductor acquisition that was abandoned, and above all a controlling stake in US biotech Abpro. Almost all of that capital was lost. Green Economy's estimate of about KRW 150 bn of impairments in roughly a year is far larger than the company's current market value of about KRW 18 bn. Abpro's Nasdaq delisting, the dismissal of its R&D staff, its going-concern qualification and the departure of Celltrion's nominee director together end the biotech thesis in practice. ABP-102 survives only as a partner-dependent option.
The replacement strategy, entertainment and content under a newly formed controlling shareholder with negligible assets and borrowed acquisition funds, has no disclosed assets, contracts or management track record. Meanwhile the one real business, compact machine tools, saw separate revenue fall by roughly three-quarters in FY2025. A revenue residual of about KRW 27 bn keeps consolidated sales flat, but its origin is undisclosed and it cannot be relied on.
Valuation looks low on paper at a P/B of about 0.35x. Book value, however, has a history of rapid impairment, and the 90% capital reduction and share consolidation were technical moves to preserve the listing rather than signs of improving fundamentals. The near-term question is listing survival: capital impairment, price and market-cap thresholds all bind at once. For institutional purposes, RootK should be classified as a distressed, high-governance-risk micro-cap. It is suitable only for special-situation monitoring, not fundamental investment. Upside would require transparent disclosure of the revenue residual, a credible arm's-length asset injection, and evidence that new capital is no longer flowing to related or opaque counterparties. None of these conditions is currently met.
Principal sources consulted
-
Green Economy Newspaper (녹색경제신문): "에이비프로바이오 톺아보기" series, 20 Mar 2026, 7 Apr 2026; 8 Jun 2026
-
Edaily: control change report (17 Mar 2026); largest-shareholder disclosures (2021; May 2025)
-
Digital Today via Nate News: change of largest shareholder to Returns (31 Mar – 1 Apr 2026)
-
Nate / Money Game: financing and Returns profile (17 Mar 2026)
-
Press9: name change to RootK and director appointments (May 2026)
-
Seoul Economic Daily: 10:1 capital reduction (Jan 2026)
-
Asia Economy: SITC 2025 / company history (5 Nov 2025); ABP-201 licence (31 Oct 2019); SMEC (Jul–Aug 2025)
-
Dealsite: 2020 CEO interview; Genictics deal (Sep 2022); machine tool peers (2026); Genictics (Sep 2026)
-
IB Tomato: loss history and current ratios (2023); Genictics/Halo (2024)
-
Newsis: Genictics deal termination background (Jul 2024)
-
Fnnews: KOSDAQ administrative-issue designations (Aug 2026)
-
ChickStock, Meerae AI, KStock, Judal, Catch, Saramin, IRGO, Korean Wikipedia (RootK), Simply Wall St (S&P Global data), Alpha Spread
-
SEC EDGAR: Abpro Holdings, Inc. 8-K Ex. 99.1 (9 Dec 2025); 10-Q Q2 2026; roic.ai, Yahoo Finance and fool.com profiles of Abpro Holdings; Zonebourse Abpro news list
-
Company IR presentation, 27 Nov 2019 (Alphasquare archive)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Prior roles / notes |
|---|---|---|---|
Kim Yong-woon (김용운) | CEO; inside director | CEO since 31 Mar 2026; director since 26 Mar 2026 AGM | Background not publicly disclosed |
Kim Jae-beom (김재범) | Inside director | Since 26 Mar 2026 | — |
Lee Hwan-jin (이환진) | Inside director | Since 26 Mar 2026 | — |
Son Bu-kwan (손부관) | Inside director | Since 26 Mar 2026 | — |
Board & Management Changes
| Period | CEO | Notes | Source |
|---|---|---|---|
Until 2016 | Founder era (Lee Hyun-woo, chairman) | Ugint founder | Edaily, Mar 2026 |
c.2019/2020 – Aug 2022 | Yang Jin-sang & Ian Yan Pui Chan (co-CEOs) | Chan was also chairman/CEO of Abpro | Saramin; Press9 |
Aug 2022 – Apr 2024 | Yang Jin-sang (sole CEO) | Led the biotech pivot narrative | Saramin; Dealsite, 2020 |
Apr 2024 – Mar 2026 | Lee Jae-yong (이재용) | Resigned at the control change | Press9 |
31 Mar 2026 – present | Kim Yong-woon | Appointed by the board after the control change | Press9 |
Major Shareholders
| Holder | Shares | Stake | Date | Source |
|---|---|---|---|---|
Returns Co., Ltd. (largest shareholder; Lee Sung-jae owns 45% of Returns) | 4,106,776 | 12.60% | 31 Mar 2026 | Digital Today/Nate |
Polymeth Investment Association & related parties (previous largest shareholder group) | 2,046,755 (5,020,981 shown in one disclosure field) | 7.19% | Pre-31 Mar 2026 | Digital Today/Nate |
Polymeth Investment Association (standalone) | ~1.13 m (post-reduction basis) | 3.97% | Mar 2026 | Nate/Money Game; Nate, May 2025 |
Veritas Investment Association | 1,135,506 pledged to Mobidick Asset Lending (KRW 1.3 bn), with change-of-control effect | 3.97% | 30 May 2025 | Edaily via Nate |
Institutional top 10 | ND; Meerae AI shows negligible foreign/institutional net flows | — | 2026 | Meerae AI |
Competitive Landscape
Key Competitors
| # | Competitor | HQ | Relevance | Verified financials | Source |
|---|---|---|---|---|---|
| 1 | DN Solutions (formerly Doosan Machine Tools) | Korea | Korea's largest machine tool maker; full MCT line-up | FY2025 consolidated revenue KRW 2,206.6 bn; operating profit KRW 411.6 bn | Dealsite, 2026 |
| 2 | SMEC (스맥) | Korea | Machine tools and automation; acquired WIA Machine Tools (ex-Hyundai WIA division) in Jul 2025 for KRW 340 bn total (SMEC share KRW 118.3 bn / 34.8%) | H1 2025 consolidated revenue KRW 77.1 bn; operating profit KRW 3.24 bn | Asia Economy, Jul & Aug 2025 |
| 3 | WIA Machine Tools (위아공작기계) | Korea | Former Hyundai WIA machine tool division | — | Asia Economy, Jul 2025 |
| 4 | Hwacheon Machinery (화천기계) | Korea | Machine tools and auto parts | FY2025 separate revenue KRW 214.5 bn; operating profit KRW 0.2 bn | Dealsite, 2026 |
| 5 | Brother Industries (Speedio) | Japan | Global leader in compact tapping/drilling centres (product overlap) | Not compiled in this research | — |
| 6 | FANUC (Robodrill) | Japan | Compact vertical machining centres | Not compiled | — |
| 7 | DMG Mori | Japan/Germany | Broad machining centre range | Not compiled | — |
| 8 | Yamazaki Mazak | Japan | Broad machining centre range | Not compiled | — |
| 9 | Okuma | Japan | Machining centres | Not compiled | — |
| 10 | Makino | Japan | Machining centres | Not compiled | — |
Peer Comparison FY2025
| Metric | RootK (FY2025, consolidated) | DN Solutions (FY2025, consolidated) | Hwacheon Machinery (FY2025, separate) | SMEC (H1 2025, consolidated) |
|---|---|---|---|---|
Revenue (KRW Bn) | 31.9 | 2,206.6 | 214.5 | 77.1 |
Operating profit (KRW Bn) | -9.3 | 411.6 | 0.2 | 3.24 |
Operating margin (%) | -29.2 | 18.7 | 0.1 | 4.2 |
Revenue growth (%) | 0.8 | — | — | negative YoY (amount ND) |



